Ultragenyx Pharmaceutical Inc (RARE) Expected to Post Quarterly Sales of $9.94 Million

Wall Street analysts predict that Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) will announce $9.94 million in sales for the current fiscal quarter, according to Zacks Investment Research. Nine analysts have provided estimates for Ultragenyx Pharmaceutical’s earnings, with the lowest sales estimate coming in at $4.91 million and the highest estimate coming in at $18.92 million. Ultragenyx Pharmaceutical posted sales of $200,000.00 during the same quarter last year, which suggests a positive year-over-year growth rate of 4,870%. The company is expected to issue its next quarterly earnings results on Thursday, November 1st.

According to Zacks, analysts expect that Ultragenyx Pharmaceutical will report full-year sales of $46.08 million for the current financial year, with estimates ranging from $25.22 million to $72.18 million. For the next financial year, analysts forecast that the company will post sales of $101.60 million per share, with estimates ranging from $74.10 million to $144.81 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research analysts that cover Ultragenyx Pharmaceutical.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($1.06) EPS for the quarter, beating the consensus estimate of ($2.08) by $1.02. Ultragenyx Pharmaceutical had a negative net margin of 703.27% and a negative return on equity of 44.09%. The business had revenue of $12.79 million during the quarter, compared to analysts’ expectations of $5.63 million. During the same period in the previous year, the business posted ($1.72) EPS.

Several analysts have commented on the stock. credit cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $67.00 to $80.00 in a research note on Thursday, June 21st. BidaskClub upgraded shares of Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 1st. Bank of America lifted their price objective on shares of Ultragenyx Pharmaceutical from $72.00 to $94.00 and gave the company a “buy” rating in a research note on Tuesday, September 11th. Wedbush lifted their price objective on shares of Ultragenyx Pharmaceutical from $71.00 to $80.00 and gave the company an “outperform” rating in a research note on Monday, August 6th. Finally, Credit Suisse Group cut shares of Ultragenyx Pharmaceutical from an “outperform” rating to a “neutral” rating and lifted their price objective for the company from $67.00 to $80.00 in a research note on Thursday, June 21st. They noted that the move was a valuation call. Four analysts have rated the stock with a hold rating, fifteen have issued a buy rating and three have assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $84.88.

Shares of NASDAQ RARE opened at $86.80 on Friday. Ultragenyx Pharmaceutical has a 12 month low of $41.67 and a 12 month high of $88.41.

In related news, EVP Karah Herdman Parschauer sold 1,226 shares of the business’s stock in a transaction on Thursday, June 21st. The shares were sold at an average price of $82.77, for a total value of $101,476.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, Director William Aliski sold 3,750 shares of the business’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $76.66, for a total transaction of $287,475.00. Following the completion of the transaction, the director now owns 72,610 shares of the company’s stock, valued at $5,566,282.60. The disclosure for this sale can be found here. Over the last quarter, insiders sold 9,976 shares of company stock valued at $781,601. Company insiders own 8.40% of the company’s stock.

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Xact Kapitalforvaltning AB increased its holdings in Ultragenyx Pharmaceutical by 10.6% in the 2nd quarter. Xact Kapitalforvaltning AB now owns 7,323 shares of the biopharmaceutical company’s stock worth $563,000 after acquiring an additional 700 shares in the last quarter. Profund Advisors LLC increased its holdings in Ultragenyx Pharmaceutical by 5.6% in the 1st quarter. Profund Advisors LLC now owns 16,653 shares of the biopharmaceutical company’s stock worth $849,000 after acquiring an additional 889 shares in the last quarter. American Century Companies Inc. increased its holdings in Ultragenyx Pharmaceutical by 2.8% in the 1st quarter. American Century Companies Inc. now owns 36,720 shares of the biopharmaceutical company’s stock worth $1,872,000 after acquiring an additional 997 shares in the last quarter. GAM Holding AG increased its holdings in Ultragenyx Pharmaceutical by 2.0% in the 2nd quarter. GAM Holding AG now owns 50,700 shares of the biopharmaceutical company’s stock worth $3,897,000 after acquiring an additional 1,000 shares in the last quarter. Finally, Metropolitan Life Insurance Co. NY increased its holdings in Ultragenyx Pharmaceutical by 7.3% in the 2nd quarter. Metropolitan Life Insurance Co. NY now owns 15,187 shares of the biopharmaceutical company’s stock worth $1,167,000 after acquiring an additional 1,037 shares in the last quarter. Hedge funds and other institutional investors own 96.22% of the company’s stock.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

See Also: Stock Symbols and CUSIP Explained

Get a free copy of the Zacks research report on Ultragenyx Pharmaceutical (RARE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply